Education
About Us
Working with TipRanks
Follow Us
Kura Oncology (DE:KUR)
FRANKFURT:KUR
Earnings Data
Report Date
Mar 03, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.19Same Quarter Last Year
Strong Buy
Based on 13 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a strong focus on advancing clinical development, particularly for ziftomenib, with significant progress in trials and preparations for a potential FDA approval. Despite financial challenges, the company's strategic partnerships and clinical advancements position it well for future growth. The sentiment is positive, driven by strong clinical and commercial progress.Company Guidance
Progress in Ziftomenib Development
Ziftomenib's FDA review for relapsed and refractory NPM1-mutated AML is on track with a PDUFA target action date of November 30, 2025. The drug has shown promising clinical data with a differentiated and favorable benefit-risk profile.
Advancements in Clinical Trials
Kura has advanced its KOMET-017 Phase III trials for ziftomenib in frontline settings with over 150 global sites targeted for enrollment. The trials aim to establish ziftomenib as a cornerstone therapy in AML treatment.
Strong Financial Position
Kura reported pro forma cash of $609.7 million, including recent milestone payments, sufficient to fund operations through 2027.
Farnesyl Transferase Inhibitor Potential
Positive clinical data for FTIs, including darlafarnib, show potential for combinations with major targeted therapies, representing a substantial commercial opportunity.
DE:KUR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:KUR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 04, 2025 | €8.76 | €8.36 | -4.48% |
Aug 07, 2025 | €5.10 | €5.02 | -1.53% |
Feb 26, 2025 | €7.45 | €7.60 | +2.04% |
Nov 07, 2024 | €16.41 | €16.27 | -0.82% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Kura Oncology (DE:KUR) report earnings?
Kura Oncology (DE:KUR) is schdueled to report earning on Mar 03, 2026, After Close (Confirmed).
What is Kura Oncology (DE:KUR) earnings time?
Kura Oncology (DE:KUR) earnings time is at Mar 03, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Kura Oncology stock?
The P/E ratio of Kura Oncology is N/A.
What is DE:KUR EPS forecast?
DE:KUR EPS forecast for the fiscal quarter 2025 (Q4) is -0.19.